Eyenovia Inc (EYEN)
1.01
+0.07
(+7.74%)
USD |
NASDAQ |
May 03, 16:00
1.02
+0.01
(+0.99%)
After-Hours: 20:00
Eyenovia Research and Development Expense (Annual): 12.98M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.98M |
| December 31, 2022 | 13.38M |
| December 31, 2021 | 14.85M |
| December 31, 2020 | 13.36M |
| December 31, 2019 | 14.10M |
| Date | Value |
|---|---|
| December 31, 2018 | 11.12M |
| December 31, 2017 | 3.817M |
| December 31, 2016 | 2.966M |
| December 31, 2015 | 2.783M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
12.98M
Minimum
2023
14.85M
Maximum
2021
13.73M
Average
13.38M
Median
2022
Research and Development Expense (Annual) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.068M |
| Alpine Immune Sciences Inc | 80.90M |
| Lantern Pharma Inc | 11.89M |
| Oragenics Inc | 15.49M |
| MAIA Biotechnology Inc | 11.11M |